Why Ozempic Doesn't Work for Everyone

Join Dr. Ben Synth as he uncovers why Ozempic works like magic for some but fails for others—exploring DNA, gut bacteria, dropout rates, and real-world factors clinical trials miss. If you're considering GLP-1 drugs, this series reveals the critical science behind personalized weight loss nobody's talking about.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Host Ben Synth examines why 68% of patients discontinue Ozempic or Wegovy within one year, exploring cost barriers, side effects, dosing gaps, and metabolic plateaus driving mass discontinuation. Covers real-world adherence data showing weight regain after stopping, financial obstacles, and systemic failures underlying the GLP-1 dropout crisis.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Ben Synth explores how gut bacteria may determine GLP-1 drug effectiveness, examining research on microbiome diversity, beneficial species like Akkermansia muciniphila, and why Ozempic works dramatically for some while failing others. Discover the hidden biological factors behind response variability in this science-driven investigation.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Ben Synth explores why 14-15% of people taking GLP-1 drugs like Ozempic see no weight loss despite weekly injections. The episode examines pharmacogenomics research revealing how genetic variants in the GLP-1 receptor gene and other DNA factors may predetermine drug effectiveness before treatment even begins, and discusses emerging genetic testing that could revolutionize personalized obesity treatment.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.